Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)

Exclusion Criteria

• •1. For females: pregnant and/or lactating or planning to become pregnant during the clinical investigation
• •2. History of allergies or hypersensitivity to HA preparations, lidocaine or anesthetics of any amide-based anesthetic
• •3. Since Juvéderm® Ultra XC contains trace amounts of Gram-positive bacterial proteins, subjects with history of allergies to such material can not be included in this clinical investigation
• •4. Tendency to keloid formation, hypertrophic scars and/or pigmentation disorders
• •5. Known human immune deficiency virus-positive individuals
• •6. Presence of infectious, inflammatory or proliferative cancerous or pre-cancerous lesions in the area to be treated
• •7. Re-current herpes simplex in the treatment area
• •8. History or presence of any autoimmune or connective tissue disease, or current treatment with immunomodulating therapy
• •9. Uncontrolled (or instable) diabetes mellitus or systemic diseases
• •10. Facial plastic surgery, tissue augmentation with silicone, fat or another non-absorbable substance (permanent fillers) area of device application
• •11. Implantation of facial dermal fillers in the treatment area in the preceding twelve months
• •12. Skin of the nasolabial region affected by aesthetic treatments (e.g. laser therapy, absorbable and non-absorbable sutures (threads), microneedling and/or botulinum toxin within the last twelve months, dermabrasion and mesotherapy within the last six months, chemical peeling within the last three months) or planning to undergo such procedures during the clinical investigation
• •13. Facial lypolysis, including submental fat treatments, within last month prior to enrollment and during the clinical investigation
• •14. Bariatric surgery within 12 months prior to enrollement and during the clinical investigation
• •15. History of bleeding disorders and/or use of anticoagulant, antiplatelet or thrombolytic medication from ten days pre- to three days post injection
• •16. Planned dental/oral surgery or modification (bridge-work, implants) within two weeks prior injection and to a minimum of four weeks post injection
• •17. Any medical condition prohibiting the inclusion in the clinical investigation according to the judgment of the treating investigator
• •18. Previous enrollment in this clinical investigation
• •19. Current participation in another clinical investigation, or treatment with any investigational drug/medical device within 30 days prior to clinical investigation enrollment
• •20. Any dependency of the subject to the treating investigator, the blinded independent evaluating investigator or clinical investigation site (e.g. employees of the sponsor), or subjects who are employees or relatives of the treating investigator and/or the independent blinded evaluating investigator
• •21. Subjects who have one of the following assessments during the visual examinations at Baseline:
• •Snellen visual acuity test worse than 20/40 (with corrective eyewear, if applicable), abnormal confrontational visual field test, or abnormal ocular motility test.
• •1. Occurrence of an SAE or adverse event of special interest (AESI; i.e., changes in vision \[loss of vision, blurriness, double vision, pain in or around the eye, blindness, blind spots, problems moving the eyes, change in peripheral vision\], skin changing color around the eyelids or around the site of injection) during or after the initial injection and/or touch-up injection
• •2. Subjects who experienced visual changes or other serious medical conditions during or after the initial/touch-up injection
• •3. Subjects who have one of the following assessments during the visual examinations:
• •* Snellen acuity test worse than 20/40 (with corrective eyewear, if applicable)
• •* abnormal confrontational visual field test
• •* abnormal ocular motility test
• •4. Subjects who became pregnant since start of the study or are planning to become pregnant during the clinical investigation
• •5. Known human immune deficiency virus-positive individuals
• •6. Presence of infectious, inflammatory or proliferative cancerous or pre-cancerous lesions in the area to be treated
• •7. Development of recurrent herpes simplex in the treatment area since study start
• •8. Development of any autoimmune or connective tissue disease since start of participation in the study, or current treatment with immunomodulating therapy
• •9. Development of uncontrolled (or instable) diabetes mellitus or any other systemic disease since study start
• •10. Development of a bleeding disorder since study start or use of anticoagulant, antiplatelet or thrombolytic medication from ten days pre- to three days post injection
• •11. Planned dental/oral surgery or modification (bridge-work, implants) within 2 weeks prior to injection and to a minimum of four weeks post injection
• •12. Any medical condition prohibiting the inclusion for repeat treatment according to the judgement of the treating investigator